Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China

Chinese Medical Journal

Volumn 123, Issue 22, 2010, Pages 3184-3192

  Gao, Yan ^a   Ning, Guang ^b   Jia, Wei Ping ^b   Zhou, Zhi Guang ^c   Xu, Zhang Rong ^d   Liu, Zhi Min ^e   Liu, Chao ^f   Ma, Jian Hua ^g   Li, Qiang ^h   Cheng, Lu Lu ⁱ   Wen, Chong Yuan ^j   Zhang, Shu Yu ^j   Zhang, Qi ^k   Desaiah, Durisala ^k   Skljarevski, Vladimir ^k  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d 306 HOSPITAL OF PLA   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^g NANJING MEDICAL UNIVERSITY   (China)

^h THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

ⁱ HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^j RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^k ELI LILLY AND COMPANY   (United States)

more..

Author keywords

Chinese patients; Clinical trial; Diabetic peripheral neuropathic pain; Duloxetine

Indexed keywords

DULOXETINE; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ANALGESIA; ANOREXIA; ARTICLE; ASTHENIA; ATHENS INSOMNIA SCALE; BEDTIME DOSAGE; BRIEF PAIN INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIABETIC NEUROPATHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; EUROQOL QUESTINNAIRE 5 DIMENSIONS; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; LETHARGY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PATIENT GLOBAL IMPRESSION OF IMPROVEMENT; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; STOMACH DISCOMFORT; VOMITING; WALKING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; AGED; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; THIOPHENES; TREATMENT OUTCOME;

EID: 79251486666     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.22.003     Document Type: Article

References (47)

1. Diabetes. World Health Organization. 2008. (Accessed May 2, 2009 at http://www.who.int/mediacentre/factsheets/fs312/en/)
2. Eastman RC. Neuropathy in diabetes. In: National Diabetes Data Group, eds. Diabetes in America, 2nd ed. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995: 339-348. NIH publication 95-1468.
3. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev 2003; 19 Suppl 1: S2-S8.
4. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006; 81 (4 Suppl): S3-S11.
5. Fields HL, Martin JB. Pain: pathophysiology and management. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine, 14th ed. New York, NY: McGraw-Hill; 1998: 55-58.
6. Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002; 18: 343-349.
7. Krause SJ, Backonja MM. Development of neuropathic pain questionnaire. Clin J Pain 2003; 19: 306-314.
8. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-128.
9. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88: 947-999.
10. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984; 7: 309-338.
11. Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res 1993; 616: 200-210.
12. Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 1997; 20: 404-419.
13. Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9.
14. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001; 26: 30-36.
15. Magni G. The use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs 1991; 42: 730-748.
16. Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000; 7: 31-47.
17. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-118.
18. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006; 7: 373-385.
19. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-1420.
20. Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006; 9: 29-40.
21. Wernicke JF, Wang F, Pritchett YL, Smith T, Raskin J, D'Souza DN, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007; 8: 503-513.
22. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-138.
23. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281-1289.
24. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicidal Ideation. J Consult Clin Psychol 1979; 47: 343-352.
25. Guy W. ECDEU assessment manual for psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, and Welfare, National Institute of Mental Health; 1976: 76-338.
26. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000; 48: 555-560.
27. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346-356.
28. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-158.
29. Weisenberg M, Kreindler ML, Schachat R, Werboff J. Pain: anxiety and attitudes in Black, white and Puerto Rican patients. Psychosom Med 1975; 37: 123-135.
30. Flannery RB Jr, Sos J, McGovern P. Ethnicity as a factor in the expression of pain. Psychosomatics 1981; 22: 39-40, 45, 49-50.
31. Weisenberg M, Caspi Z. Cultural and educational influences on pain of childbirth. J Pain Symptom Manage 1989; 4: 13-19.
32. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002; 94 (10 Suppl): 1-26.
33. Johnson M, Din A. Ethnocultural differences in the analgesic effects of placebo transcutaneous electrical nerve stimulation on cold-induced pain in healthy subjects: a preliminary study. Complement Ther Med 1997; 5: 74-79.
34. Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002; 22: 416-423.
35. Wang SJ, Fuh JL, Wu ZA. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc 2007; 70: 39-46.
36. Guo YL, Zhu JC, Pan TM, Ding Q, Wang YX, Cheong NF, et al. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. Int J Urol 2006; 13: 721-727.
37. Chen KK, Jiann BP, Lin JS, Lee SS, Huang ST, Wang CJ, et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med 2004; 1: 201-208.
38. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003; 28: 552-557.
39. Olson C, Neeper S. Why clinical trials fail. Surrey, UK: Brookwood Medical Publications; 1997.
40. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005; 65 Suppl 4: S32-S49.
41. Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Drug Metab Res Rev 2009; 25: 623-631.
42. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974-2984.
43. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5-15.
44. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136: 432-444.
45. Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009; 146: 253-260.
46. Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke M, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010; In press.
47. Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007; 16: 1145-1156.